Pediatric Drugs

, Volume 10, Issue 3, pp 177–192

Epidemiology and Management Options for Colorectal Cancer in Children

Therapy In Practice

Abstract

Colorectal carcinoma (CRC), although primarily a disease of adulthood, accounts for 2% of malignancies in adolescents and has been reported in children as young as 9 months of age. Our knowledge of CRC in pediatrics is based on a handful of case series and case reports. Apart from one small clinical trial, there has been a lack of prospective clinical studies in this age group. Based on these published reports, most CRC in children is sporadic, but it can also arise in the setting of predisposing conditions, such as gastrointestinal polyposis syndromes, nonpolyposis familial cancer syndromes, and inflammatory bowel disease. Despite some similarities to adult disease, CRC in childhood may be intrinsically different biologically, because it differs from adult-onset CRC in several respects. Childhood CRC tends to be diagnosed at an advanced stage, is largely of mucinous histology, and (probably because of these features) tends to have a poorer outcome. As a result of its rarity in children and the lack of prospective pediatric studies, recommendations for therapy are primarily extrapolated from adult clinical trials. A review of pediatric case series in the English literature emphasizes the prognostic significance of stage of disease, as well as extent of surgical resection. As in adults, early detection is critical in an effort to capture the disease at less advanced stages. Complete surgical resection with aggressive lymph node dissection is essential for cure, and neoadjuvant chemotherapy may be used in an effort to render unresectable lesions resectable. Active agents in adults with CRC include fluorouracil, folinic acid (leucovorin), oxaliplatin, and irinotecan. Furthermore, newer targeted therapeutic agents, such as bevacizumab and cetuximab, have added additional efficacy to the standard chemotherapy backbone. Collaborative multi-institutional pediatric clinical trials are needed to evaluate the prognosis, optimal treatment response, and the basic biology of childhood onset CRC.

References

  1. 1.
    Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia (PA): Lippincott Williams & Wilkins, 2006Google Scholar
  2. 2.
    Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer 2000; 88: 2398–424PubMedGoogle Scholar
  3. 3.
    Fairley TL, Cardinez CJ, Martin J, et al. Colorectal cancer in U.S. adults younger than 50 years of age, 1998–2001. Cancer 2006; 107: 1153–61PubMedGoogle Scholar
  4. 4.
    Bleyer A, O’Leary M, Barr R, et al., editors. Cancer epidemiology in older adolescents and young adults 15–29 years of age, including SEER incidence and survival: 1975–2000. Bethesda (MD): National Cancer Institute, 2006: NIH pub. no: 06-5767Google Scholar
  5. 5.
    Hill DA, Furman WL, Billups CA, et al. Colorectal carcinoma in childhood and adolescence: a clinicopathologic review of 77 cases. J Clin Oncol 1007; 25(36): 5808–14Google Scholar
  6. 6.
    Andersson A, Bergdahl L. Carcinoma of the colon in children: a report of six new cases and a review of the literature. J Pediatr Surg 1976; 11: 967–71PubMedGoogle Scholar
  7. 7.
    Middelkamp JN, Haffner H. Carcinoma of the colon in children. Pediatrics 1963; 32: 558–71PubMedGoogle Scholar
  8. 8.
    Taguchi T, Suita S, Hirata Y, et al. Carcinoma of the colon in children: a case report and review of 41 Japanese cases. J Pediatr Gastroenterol Nutr 1991; 12: 394–9PubMedGoogle Scholar
  9. 9.
    Ferrari A, Rognone A, Casanova M, et al. Colorectal carcinoma in children and adolescents: the experience of the Istituto Nazionale Tumori of Milan, Italy. Pediatr Blood Cancer 2007; 50(3): 588–93Google Scholar
  10. 10.
    Goldthorn JF, Powars D, Hays DM. Adenocarcinoma of the colon and rectum in the adolescent. Surgery 1983; 93: 409–14PubMedGoogle Scholar
  11. 11.
    Lamego CM, Torloni H. Colorectal adenocarcinoma in childhood and adolescent: report of 11 cases and review of the literature. Pediatr Radiol 1989; 19: 504–8PubMedGoogle Scholar
  12. 12.
    Brown RA, Rode H, Millar AJ, et al. Colorectal carcinoma in children. J Pediatr Surg 1992; 27: 919–21PubMedGoogle Scholar
  13. 13.
    Shahrudin MD, Noori SM. Cancer of the colon and rectum in the first three decades of life. Hepatogastroenterology 1997; 44: 441–4PubMedGoogle Scholar
  14. 14.
    Karnak I, Ciftci AO, Senocak ME, et al. Colorectal carcinoma in children. J Pediatr Surg 1999; 34: 1499–504PubMedGoogle Scholar
  15. 15.
    Bhatia MS, Chandna S, Shah R, et al. Colorectal carcinoma in Indian children. Indian Pediatr 2000; 37: 1353–8PubMedGoogle Scholar
  16. 16.
    Vastyan AM, Walker J, Pinter AB, et al. Colorectal carcinoma in children and adolescents: a report of seven cases. Eur J Pediatr Surg 2001; 11: 338–41PubMedGoogle Scholar
  17. 17.
    Durno C, Aronson M, Bapat B, et al. Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma. Gut 2005; 54: 1146–50PubMedGoogle Scholar
  18. 18.
    Chantada GL, Perelli VB, Lombardi MG, et al. Colorectal carcinoma in children, adolescents, and young adults. J Pediatr Hematol Oncol 2005; 27: 39–41PubMedGoogle Scholar
  19. 19.
    Sessions RT, Riddell DH, Kaplan HJ, et al. Carcinoma of the colon in the first two decades of life. Ann Surg 1965; 162: 279–84PubMedGoogle Scholar
  20. 20.
    LaQuaglia MP, Heller G, Filippa DA, et al. Prognostic factors and outcome in patients 21 years and under with colorectal carcinoma. J Pediatr Surg 1992; 27: 1085–9PubMedGoogle Scholar
  21. 21.
    Radhakrishnan CN, Bruce J. Colorectal cancers in children without any predisposing factors. A report of eight cases and review of the literature. Eur J Pediatr Surg 2003; 13: 66–8PubMedGoogle Scholar
  22. 22.
    Lewis CT, Riley WE, Georgeson K, et al. Carcinoma of the colon and rectum in patients less than 20 years of age. South Med J 1990; 83: 383–5PubMedGoogle Scholar
  23. 23.
    McGahren III ED, Mills SE, Wilhelm MC, et al. Colorectal carcinoma in patients 30 years of age and younger. Am Surg 1995; 61: 78–82PubMedGoogle Scholar
  24. 24.
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–67PubMedGoogle Scholar
  25. 25.
    Morson BC. Genesis of colorectal cancer. Clin Gastroenterol 1976; 5: 505–25PubMedGoogle Scholar
  26. 26.
    Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525–32PubMedGoogle Scholar
  27. 27.
    Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50: 7717–22PubMedGoogle Scholar
  28. 28.
    Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977–81PubMedGoogle Scholar
  29. 29.
    Winawer SJ, Zauber AG, O’Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993; 328: 901–6PubMedGoogle Scholar
  30. 30.
    Kern WH, White WC. Adenocarcinoma of the colon in a 9-month-old infant; report of a case. Cancer 1958; 11: 855–7PubMedGoogle Scholar
  31. 31.
    Chabalko JJ, Fraumeni Jr JF. Colorectal cancer in children: epidemiologic aspects. Dis Colon Rectum 1975; 18: 1–3PubMedGoogle Scholar
  32. 32.
    Ahsan H, Neugut AI, Garbowski GC, et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998; 128: 900–5PubMedGoogle Scholar
  33. 33.
    Bonelli L, Martines H, Conio M, et al. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel: a case-control study. Int J Cancer 1988; 41: 513–7PubMedGoogle Scholar
  34. 34.
    Erdman SH, Barnard JA. Gastrointestinal polyps and polyposis syndromes in children. Curr Opin Pediatr 2002; 14: 576–82PubMedGoogle Scholar
  35. 35.
    Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119: 1447–53PubMedGoogle Scholar
  36. 36.
    Chow E, Macrae F. A review of juvenile polyposis syndrome. J Gastroenterol Hepatol 2005 Nov; 20(11): 1634–40PubMedGoogle Scholar
  37. 37.
    Coburn MC, Pricolo VE, DeLuca FG, et al. Malignant potential in intestinal juvenile polyposis syndromes. Ann Surg Oncol 1995; 2: 386–91PubMedGoogle Scholar
  38. 38.
    Jass JR, Williams CB, Bussey HJ, et al. Juvenile polyposis: a precancerous condition. Histopathology 1988; 13: 619–30PubMedGoogle Scholar
  39. 39.
    Grady WM. Genetic testing for high-risk colon cancer patients. Gastroenterology 2003; 124: 1574–94PubMedGoogle Scholar
  40. 40.
    Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159–70PubMedGoogle Scholar
  41. 41.
    Rowley PT. Inherited susceptibility to colorectal cancer. Annu Rev Med 2005; 56: 539–54PubMedGoogle Scholar
  42. 42.
    Distante S, Nasioulas S, Somers GR, et al. Familial adenomatous polyposis in a 5 year old child: a clinical, pathological, and molecular genetic study. J Med Genet 1996; 33: 157–60PubMedGoogle Scholar
  43. 43.
    Burt RW. Colon cancer screening. Gastroenterology 2000; 119: 837–53PubMedGoogle Scholar
  44. 44.
    Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121: 198–213PubMedGoogle Scholar
  45. 45.
    Church JM, McGannon E, Burke C, et al. Teenagers with familial adenomatous polyposis: what is their risk for colorectal cancer? Dis Colon Rectum 2002; 45: 887–9PubMedGoogle Scholar
  46. 46.
    Schlemmer M. Desmoid tumors and deep fibromatoses. Hematol Oncol Clin North Am 2005; 19: 565–71PubMedGoogle Scholar
  47. 47.
    Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot’ s syndrome. N Engl J Med 1995; 332: 839–47PubMedGoogle Scholar
  48. 48.
    Lynch PM, Lynch HT, Harris RE. Hereditary proximal colonic cancer. Dis Colon Rectum 1977; 20: 661–8PubMedGoogle Scholar
  49. 49.
    Corredor J, Wambach J, Barnard J. Gastrointestinal polyps in children: advances in molecular genetics, diagnosis, and management. J Pediatr 2001; 138: 621–8PubMedGoogle Scholar
  50. 50.
    Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997; 113: 1146–58PubMedGoogle Scholar
  51. 51.
    Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1453–6PubMedGoogle Scholar
  52. 52.
    Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 2003; 138: 560–70PubMedGoogle Scholar
  53. 53.
    Jo WS, Chung DC. Genetics of hereditary colorectal cancer. Semin Oncol 2005; 32: 11–23PubMedGoogle Scholar
  54. 54.
    Loftus Jr EV. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am 2006; 35: 517–31PubMedGoogle Scholar
  55. 55.
    Greenstein AJ, Slater G, Heimann TM, et al. A comparison of multiple synchronous colorectal cancer in ulcerative colitis, familial polyposis coli, and de novo cancer. Ann Surg 1986; 203: 123–8PubMedGoogle Scholar
  56. 56.
    Lashner BA, Turner BC, Bostwick DG, et al. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci 1990; 35: 349–52PubMedGoogle Scholar
  57. 57.
    Holowach J, Thurston DL. Chronic ulcerative colitis in childhood. J Pediatr 1956; 48: 279–91PubMedGoogle Scholar
  58. 58.
    Jackman RJ, Bargen JA, Helmholz HF. Life histories of ninety-five children with chronic ulcerative colitis. Am J Dis Chil 1940; 59: 459–67Google Scholar
  59. 59.
    Wilcox Jr HR, Beattie JL. Carcinoma complicating ulcerative colitis during childhood. Am J Clin Pathol 1956; 26: 778–86PubMedGoogle Scholar
  60. 60.
    Hamilton SR. Colorectal carcinoma in patients with Crohn’s disease. Gastroenterology 1985; 89: 398–407PubMedGoogle Scholar
  61. 61.
    Tiszlavicz L, Kapin M, Varkonyi A, et al. Adenocarcinoma of the colon developing on the basis of Crohn’s disease in childhood. Eur J Pediatr 2001; 160: 168–72PubMedGoogle Scholar
  62. 62.
    Children’s Oncology Group Survivorship Guidelines [online]. Available from URL: http://www.survivorshipguidelines.org [Accessed 2007 Sep 15]
  63. 63.
    St John DJ, McDermott FT, Hopper JL, et al. Cancer risk in relatives of patients with common colorectal cancer. Ann Intern Med 1993; 118: 785–90PubMedGoogle Scholar
  64. 64.
    Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994; 331: 1669–74PubMedGoogle Scholar
  65. 65.
    Hall NR, Finan PJ, Ward B, et al. Genetic susceptibility to colorectal cancer in patients under 45 years of age. Br J Surg 1994; 81: 1485–9PubMedGoogle Scholar
  66. 66.
    Bhatia S, Pratt CB, Sharp GB, et al. Family history of cancer in children and young adults with colorectal cancer. Med Pediatr Oncol 1999; 33: 470–5PubMedGoogle Scholar
  67. 67.
    Datta RV, LaQuaglia MP, Paty PB. Genetic and phenotypic correlates of colorectal cancer in young patients. N Engl J Med 2000; 342: 137–8PubMedGoogle Scholar
  68. 68.
    Anfeld F. Casuitik der congenitalen neoplasm. Arch Gynaekol 1980; 16: 135–7Google Scholar
  69. 69.
    Lee YM, Law WL, Chu KW, et al. Emergency surgery for obstructing colorectal cancers: a comparison between right-sided and left-sided lesions. J Am Coll Surg 2001; 192: 719–25PubMedGoogle Scholar
  70. 70.
    Symonds DA, Vickery AL. Mucinous carcinoma of the colon and rectum. Cancer 1976; 37: 1891–900PubMedGoogle Scholar
  71. 71.
    Consorti F, Lorenzotti A, Midiri G, et al. Prognostic significance of mucinous carcinoma of colon and rectum: a prospective case-control study. J Surg Oncol 2000; 73: 70–4PubMedGoogle Scholar
  72. 72.
    Anthony T, George R, Rodriguez-Bigas M, et al. Primary signet-ring cell carcinoma of the colon and rectum. Ann Surg Oncol 1996; 3: 344–8PubMedGoogle Scholar
  73. 73.
    Negri FV, Wotherspoon A, Cunningham D, et al. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 2005; 16: 1305–10PubMedGoogle Scholar
  74. 74.
    Green JB, Timmcke AE, Mitchell WT, et al. Mucinous carcinoma: just another colon cancer? Dis Colon Rectum 1993; 36: 49–54PubMedGoogle Scholar
  75. 75.
    Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag, 2002Google Scholar
  76. 76.
    Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004; 54: 295–308PubMedGoogle Scholar
  77. 77.
    Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979–94PubMedGoogle Scholar
  78. 78.
    Sobin LH, Greene FL. TNM classification: clarification of number of regional lymph nodes for pNo [communication]. Cancer 2001; 92: 452PubMedGoogle Scholar
  79. 79.
    Rao BN, Pratt CB, Fleming ID, et al. Colon carcinoma in children and adolescents: a review of 30 cases. Cancer 1985; 55: 1322–6PubMedGoogle Scholar
  80. 80.
    Park IJ, Kim HC, Yu CS, et al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol 2006; 32: 941–7PubMedGoogle Scholar
  81. 81.
    Delbeke D, Martin WH. PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 2004; 34: 209–23PubMedGoogle Scholar
  82. 82.
    Cohade C, Osman M, Leal J, et al. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003; 44: 1797–803PubMedGoogle Scholar
  83. 83.
    Berger KL, Nicholson SA, Dehdashti F, et al. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 2000; 174: 1005–8PubMedGoogle Scholar
  84. 84.
    Pratt CB, Rao BN, Merchant TE, et al. Treatment of colorectal carcinoma in adolescents and young adults with surgery, 5-fluorouracil/leucovorin/inter-feron-alpha 2a and radiation therapy. Med Pediatr Oncol 1999; 32: 459–60PubMedGoogle Scholar
  85. 85.
    Markowitz AJ, Winawer SJ. Management of colorectal polyps. CA Cancer J Clin 1997; 47: 93–112PubMedGoogle Scholar
  86. 86.
    National comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer [online]. Available from URL: http://www.nccn.org [Accessed 2007 Sep 15 ]
  87. 87.
    Sarli L, Bader G, Iusco D, et al. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 2005; 41: 272–9PubMedGoogle Scholar
  88. 88.
    Swanson RS, Compton CC, Stewart AK, et al. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10: 65–71PubMedGoogle Scholar
  89. 89.
    Andre T, Sargent D, Tabernero J, et al. Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 2006; 13: 887–98PubMedGoogle Scholar
  90. 90.
    Berger AC, Sigurdson ER, Le Voyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005; 23: 8706–12PubMedGoogle Scholar
  91. 91.
    Newland RC, Dent OF, Lyttle MN, et al. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 1994; 73: 2076–82PubMedGoogle Scholar
  92. 92.
    Chapuis PH, Dent OF, Bokey EL, et al. Adverse histopathological findings as a guide to patient management after curative resection of node-positive colonic cancer. Br J Surg 2004; 91: 349–54PubMedGoogle Scholar
  93. 93.
    Wiese DA, Saha S, Badin J, et al. Pathologic evaluation of sentinel lymph nodes in colorectal carcinoma. Arch Pathol Lab Med 2000; 124: 1759–63PubMedGoogle Scholar
  94. 94.
    Bertagnolli M, Miedema B, Redston M, et al. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg 2004; 240: 624–8PubMedGoogle Scholar
  95. 95.
    Oberg A, Stenling R, Tavelin B, et al. Are lymph node micrometastases of any clinical significance in Dukes Stages A and B colorectal cancer? Dis Colon Rectum 1998; 41: 1244–9PubMedGoogle Scholar
  96. 96.
    Turner RR, Nora DT, Trocha SD, et al. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes. Arch Pathol Lab Med 2003; 127: 673–9PubMedGoogle Scholar
  97. 97.
    Saha S, Dan AG, Beutler T, et al. Sentinel lymph node mapping technique in colon cancer. Semin Oncol 2004; 31: 374–81PubMedGoogle Scholar
  98. 98.
    Cooper HS, Deppisch LM, Gourley WK, et al. Endoscopically removed malignant colorectal polyps: clinicopathologic correlations. Gastroenterology 1995; 108: 1657–65PubMedGoogle Scholar
  99. 99.
    Cohen AM. Surgical considerations in patients with cancer of the colon and rectum. Semin Oncol 1991; 18: 381–7PubMedGoogle Scholar
  100. 100.
    Haggitt RC, Glotzbach RE, Soffer EE, et al. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 1985; 89: 328–36PubMedGoogle Scholar
  101. 101.
    Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797–806PubMedGoogle Scholar
  102. 102.
    Benson III AB, Schrag D, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408–19PubMedGoogle Scholar
  103. 103.
    Waterston AM, Cassidy J. Adjuvant treatment strategies for early colon cancer. Drugs 2005; 65: 1935–47PubMedGoogle Scholar
  104. 104.
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45PubMedGoogle Scholar
  105. 105.
    Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60–5PubMedGoogle Scholar
  106. 106.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42PubMedGoogle Scholar
  107. 107.
    Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706–12PubMedGoogle Scholar
  108. 108.
    Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23–30PubMedGoogle Scholar
  109. 109.
    Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005; 23(22): 4866–75PubMedGoogle Scholar
  110. 110.
    Grothey A. Is there a third-line therapy for metastatic colorectal cancer? Semin Oncol 2006 Dec; 33 (6 Suppl. 11): S36–8PubMedGoogle Scholar
  111. 111.
    Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905–14PubMedGoogle Scholar
  112. 112.
    O’Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246–50PubMedGoogle Scholar
  113. 113.
    Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluoro-uracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17: 3553–9PubMedGoogle Scholar
  114. 114.
    Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696–704PubMedGoogle Scholar
  115. 115.
    Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343–51PubMedGoogle Scholar
  116. 116.
    Cheeseman SL, Joel SP, Chester JD, et al. A modified de Gramont regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002; 87: 393–9PubMedGoogle Scholar
  117. 117.
    Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23: 8671–8PubMedGoogle Scholar
  118. 118.
    de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47PubMedGoogle Scholar
  119. 119.
    International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939–44Google Scholar
  120. 120.
    Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938–46PubMedGoogle Scholar
  121. 121.
    Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818–25PubMedGoogle Scholar
  122. 122.
    McAfee MK, Allen MS, Trastek VF, et al. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992; 53: 780–5PubMedGoogle Scholar
  123. 123.
    Inoue M, Kotake Y, Nakagawa K, et al. Surgery for pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2000; 70: 380–3PubMedGoogle Scholar
  124. 124.
    Sakamoto T, Tsubota N, Iwanaga K, et al. Pulmonary resection for metastases from colorectal cancer. Chest 2001; 119: 1069–72PubMedGoogle Scholar
  125. 125.
    Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933–9PubMedGoogle Scholar
  126. 126.
    Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005; 16: 425–9PubMedGoogle Scholar
  127. 127.
    Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23: 2038–48PubMedGoogle Scholar
  128. 128.
    Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553–60PubMedGoogle Scholar
  129. 129.
    Van CE, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097–106Google Scholar
  130. 130.
    Hochster H, Kettner E, Kroning H, et al. Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. Clin Colorectal Cancer 2005; 5: 257–62PubMedGoogle Scholar
  131. 131.
    Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–7PubMedGoogle Scholar
  132. 132.
    Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502–8PubMedGoogle Scholar
  133. 133.
    Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084–91PubMedGoogle Scholar
  134. 134.
    Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children’s oncology group study. J Clin Oncol 2008; 26(3): 399–405Google Scholar
  135. 135.
    Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2005; 23: 9441–2PubMedGoogle Scholar
  136. 136.
    Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2004; 22: 1209–14PubMedGoogle Scholar
  137. 137.
    Aparicio J, Fernandez-Martos C, Vincent JM, et al. FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 2005 Nov; 5(4): 263–7PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Pediatric Hematology-OncologyAmerican University of BeirutBeirutLebanon
  2. 2.Department of OncologySt Jude Children’s Research HospitalMemphisUSA

Personalised recommendations